HealthEquity: Compounding Flywheel Reveals Attractive Entry Point

HealthEquity grew FY2026 revenue 9% to $1.313 billion, with significant margin expansion and custodial revenue up 17% on enhanced rate migration. Management expects further yield increases in FY2027, and a major low-yield contract expiry should provide an additional boost to custodial revenue. The article also highlights legislative tailwinds expanding the company’s addressable market.

Analysis

HQY’s setup is less about headline growth and more about operating leverage in a quasi-rate product embedded in healthcare payments. The key second-order effect is that the business can compound even if HSA account growth slows, because custodial balances and migration to higher-yield structures amplify revenue per dollar of assets. That makes HQY unusually sensitive to the duration of elevated short rates, but also exposes it to a future normalization where yield tailwinds fade faster than consensus models likely assume.

The competitive dynamic is asymmetric: incumbents with scale, compliance infrastructure, and sticky employer relationships should benefit most from the legislative expansion, while smaller administrators may struggle to match pricing, yield, and servicing simultaneously. The larger risk is not demand collapse, but mix shift—if employers push toward lower-balance or more transactional accounts, custodial economics can decelerate even as headline HSA adoption keeps rising. In other words, the market may be underestimating how much of the upside is coming from rate migration rather than pure unit growth.

The near-term catalyst path is clear over the next 1–3 quarters: any additional step-up in custodial yield plus the contract expiry should produce visible margin and revenue beats. The contrarian concern is that this can become a crowded “quality compounder + rates” long, which leaves the stock vulnerable if the Fed cuts faster than expected or if management guides conservatively on reinvestment rates. The right lens is not whether the business is good—it is—but whether the current multiple already discounts several quarters of yield expansion and a smooth legislative pass-through.

Key Decisions for Investors

• Long HQY into the next earnings print with a 1–2 quarter horizon; favor strength after any post-print pullback, since the market may be underpricing custodial yield upside relative to consensus.
• Use a call spread in HQY rather than outright shares for the next 3–6 months; this captures the contract-expiry and yield-migration catalyst while limiting downside if rate expectations reverse.
• Pair long HQY / short a lower-quality healthcare admin or payments processor with weaker pricing power over the next 6–12 months; the spread should benefit if legislative tailwinds widen the moat and higher yields accrue to scale players.
• If rates start to price a faster-cutting cycle, trim HQY on rallies rather than waiting for fundamentals to roll over; the stock is likely to trade on forward yield expectations well before revenue reaccelerates visibly.